Company Description

Valion Bio, Inc. operates as a late-stage biopharmaceutical company.

Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.

The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence.

In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026.

The company was incorporated in 2016 and is based in San Antonio, Texas.

Valion Bio, Inc.

Country	United States
Founded	2016
IPO Date	Nov 11, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	52
CEO	Michael Handley

Contact Details

Address: 1305 E. Houston Street, Suite 311, Building 1 San Antonio, Texas 78205 United States
Phone	888 276 6888
Website	valionbio.com

Stock Details

Ticker Symbol	VBIO
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1787740
CUSIP Number	888705308
ISIN Number	US8887053085
Employer ID	81-4016391
SIC Code	2834

Key Executives

Name	Position
Michael Kevin Handley	Chief Executive Officer and Director
Lisa G. Wolf	Chief Financial Officer and Principal Financial and Principal Accounting Officer
Melinda Lackey	General Counsel and Senior Vice President of Legal Affairs

Latest SEC Filings

Date	Type	Title
Aug 27, 2026	SCHEDULE 13D/A	Filing
Aug 27, 2026	8-K	Current Report
Aug 24, 2026	SCHEDULE 13D/A	Filing
Aug 24, 2026	RW	Filing
Aug 20, 2026	8-K/A	[Amend] Current report
Aug 19, 2026	SCHEDULE 13D/A	Filing
Aug 17, 2026	8-K	Current Report
Aug 14, 2026	SCHEDULE 13D/A	Filing
Aug 14, 2026	10-Q	Quarterly Report
Aug 12, 2026	EFFECT	Notice of Effectiveness

View All SEC Filings